Linked Life Data

19187960

Source:http://linkedlifedata.com/resource/pubmed/id/19187960

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19187960rdf:typepubmed:Citationlld:pubmed
pubmed-article:19187960lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0020789lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0040845lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0059985lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0585361lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0442967lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:19187960lifeskim:mentionsumls-concept:C0733521lld:lifeskim
pubmed-article:19187960pubmed:issue8lld:pubmed
pubmed-article:19187960pubmed:dateCreated2009-5-18lld:pubmed
pubmed-article:19187960pubmed:abstractTextPreclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine regimen. In this study 52 patients with relapsed/refractory AML obtained a complete remission (CR) rate of 69.2% after FLAIRG regimen (Fludarabine and arabinosylcytosine twice daily, idarubicin, G-CSF, ATRA). This schedule resulted effective and tolerable enabling 53% of the responding patients to receive transplant procedure. FLAIRG regimen could be proposed as a "bridge" to transplant treatment in this poor risk setting.lld:pubmed
pubmed-article:19187960pubmed:languageenglld:pubmed
pubmed-article:19187960pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:citationSubsetIMlld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19187960pubmed:statusMEDLINElld:pubmed
pubmed-article:19187960pubmed:monthAuglld:pubmed
pubmed-article:19187960pubmed:issn1873-5835lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:MontilloMarco...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:MorraEnricaElld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:NosariAnna...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:TedeschiAless...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:RicciFrancesc...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:CafroAnna...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:MarbelloLaura...lld:pubmed
pubmed-article:19187960pubmed:authorpubmed-author:NichelattiMic...lld:pubmed
pubmed-article:19187960pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19187960pubmed:volume33lld:pubmed
pubmed-article:19187960pubmed:ownerNLMlld:pubmed
pubmed-article:19187960pubmed:authorsCompleteYlld:pubmed
pubmed-article:19187960pubmed:pagination1072-8lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:meshHeadingpubmed-meshheading:19187960...lld:pubmed
pubmed-article:19187960pubmed:year2009lld:pubmed
pubmed-article:19187960pubmed:articleTitleTwice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.lld:pubmed
pubmed-article:19187960pubmed:affiliationDepartment of Oncology/Hematology, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milano, Italy. marco.montillo@ospedaleniguarda.itlld:pubmed
pubmed-article:19187960pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19187960pubmed:publicationTypeClinical Triallld:pubmed